Meditech announces positive HyDOX results
07 June, 2002 by Melissa TrudingerMeditech Research has announced that its pre-clinical animal studies for anti-cancer drug HyDOX showed a three-fold reduction of heart damage.
IDT not concerned by AstraZeneca decision on cancer drug
07 June, 2002 by Tanya HollisPharmaceutical manufacturer Institute of Drug Technology may pursue direct talks with the UK developer of an early-stage anti-cancer drug after licensee AstraZeneca dumped the project.
Progen PI-88 trials proliferate
06 June, 2002 by Pete YoungAustralian biotech Progen Industries has won ethics approval to launch a Phase I human trial for its anti-cancer drug candidate PI-88 in conjunction with established chemotherapy agent Taxotere.
Psoriasis gene cream results published
05 June, 2002 by Tanya HollisA Melbourne-developed topical antisense drug has been shown to successfully penetrate human psoriasis lesions, paving the way for better treatment of the disease.
Meditech in deal with UK's SkyePharma
04 June, 2002 by Tanya HollisPerth-based Meditech Research has signed an exclusive commercial agreement with British drug company SkyePharma giving the local biotech access to a suite of new patents.
WEHI research suggests alternative MS treatment
03 June, 2002 by Melissa TrudingerResearchers at the Walter and Eliza Hall Institute have discovered that treatment with cytokine Leukaemia Inhibitory Factor (LIF) can reverse the loss of nerve cells in a mouse model of multiple sclerosis (MS).
Biotron begins cancer detection assay trials
31 May, 2002 by Melissa TrudingerA new clinical diagnostic assay for prostate cancer detection is starting clinical trials at St Vincent's Clinic in Sydney.
US cancer institute evaluating Peplin drug
31 May, 2002 by Pete YoungThe American National Cancer Institute is scheduling advanced appraisals of an Australian anti-cancer drug which has produced impressive results in preliminary trials.
Mimotopes and Baker combine on cardio treatment
28 May, 2002 by Melissa TrudingerA letter of intent to jointly develop a new class of drugs for the treatment of congestive heart failure and other cardiovascular diseases has been signed by combinatorial and medicinal chemistry company Mimotopes and the Baker Medical Research Institute.
Share price increase follows Biotron's HIV success
28 May, 2002 by Melissa TrudingerCanberra biotech Biotron has announced that its lead anti-HIV compound, BIT009 has shown inhibition of HIV-1 replication in infected human cells.
Tocovite claims its technology delivers
27 May, 2002 by Melissa TrudingerMelbourne-based company Tocovite claims an absorption system that it has developed could improve drug delivery through the skin.
US man first to receive Sirtex cancer treatment
24 May, 2002 by Iain ScottAnti-cancer treatment SIR-Spheres, designed by Sydney-based company Sirtex, has been used on a patient for the first time since it received US Food and Drug Administration (FDA) approval in March this year.
Diabetes research offensive launched
24 May, 2002 by Tanya HollisA research and development agreement with the aim of finding an effective treatment for type II diabetes has been signed in Melbourne.
Melbourne researchers discover heart attack gene link
24 May, 2002 by Melissa TrudingerAustralian researchers have determined three genetic loci which are linked to heart attacks.
UQ researchers in bone growth breakthrough
15 May, 2002 by Pete YoungAustralian research on sugars which stimulate stem cells to become bone tissue has resulted in a biological paste that promotes healing of fractures and breaks.
